KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Share-based Compensation: 2010-2025

Historic Share-based Compensation for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $3.1 million.

  • Nektar Therapeutics' Share-based Compensation fell 43.02% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 36.59%. This contributed to the annual value of $21.6 million for FY2024, which is 35.27% down from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Share-based Compensation is $3.1 million, which was down 11.88% from $3.5 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Share-based Compensation registered a high of $24.7 million during Q3 2021, and its lowest value of $3.1 million during Q3 2025.
  • Its 3-year average for Share-based Compensation is $6.0 million, with a median of $5.4 million in 2024.
  • In the last 5 years, Nektar Therapeutics' Share-based Compensation climbed by 4.18% in 2021 and then crashed by 53.18% in 2022.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Share-based Compensation stood at $22.4 million in 2021, then crashed by 43.15% to $12.7 million in 2022, then crashed by 43.05% to $7.3 million in 2023, then plummeted by 33.79% to $4.8 million in 2024, then tumbled by 43.02% to $3.1 million in 2025.
  • Its last three reported values are $3.1 million in Q3 2025, $3.5 million for Q2 2025, and $3.9 million during Q1 2025.